Jazz pharmaceuticals plc (JAZZ)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net income (loss)

523,367

447,098

487,848

396,831

329,534

57,326

216,312

288,586

124,984

32,778

-6,836

Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Intangible asset amortization

354,814

201,498

152,065

101,994

98,162

126,584

79,042

72,922

7,448

7,825

7,668

Share-based compensation

110,563

102,441

106,900

98,771

91,550

69,638

44,551

23,006

20,704

8,219

5,957

Impairment charge

0

42,896

0

0

31,523

39,365

0

0

-

-

-

Depreciation

15,342

15,233

13,089

11,786

9,894

7,097

3,048

1,307

379

886

1,429

Acquired in-process research and development

109,975

0

85,000

23,750

0

202,626

4,988

0

-

-

-

Loss on disposal of assets

-21

-655

-473

-47

-172

-24

-46

-163

-33

-279

-14

Acquisition accounting inventory fair value step-up adjustments

-

-

-

-

-

10,477

3,826

19,939

0

0

-

Excess tax benefit from share-based compensation

-

-

-

-

-

-

0

9,785

0

0

-

Change in fair value of contingent consideration

-

-

-

-

-

-

-15,200

300

0

0

-

Deferred tax benefit

-236,610

-88,815

-225,591

-41,163

-68,358

-49,254

-10,097

-113,862

0

0

-

Gain on sale of business

-

-

-

-

-

-

-

35,244

0

0

-

Provision for losses on accounts receivable and inventory

6,668

4,728

2,190

2,209

4,062

2,493

2,446

4,654

59

-105

-

Loss on extinguishment and modification of debt

0

-1,425

0

-638

-16,815

0

-3,749

0

-1,247

-12,287

-

Amortization of debt discount and deferred financing costs

46,396

43,960

30,026

22,133

22,738

13,725

4,591

-

-

2,406

2,810

Other non-cash transactions

4,051

-4,499

-14,321

3,741

5,187

11,986

-1,687

-3,523

-394

-

-

Changes in assets and liabilities:
Accounts receivable

92,326

40,132

-12,278

25,603

24,841

55,041

48,846

4,724

12,293

9,768

5,670

Inventories

32,790

18,512

8,667

17,024

-6,271

7,630

8,516

-1,697

-1,239

1,539

-883

Prepaid expenses and other current assets

25,650

-6,697

26,874

15,700

-3,720

-11,936

13,871

13,091

934

-426

-2,610

Other non-current assets

14,830

320

-119

-267

4,573

3,060

4,306

3,491

-186

0

1,748

Operating lease assets

-14,148

-

-

-

-

-

-

-

-

-

-

Accounts payable

4,770

17,040

214

361

-2,280

-37,966

5,089

-7,286

2,080

891

-3,578

Accrued liabilities

-5,565

71,208

-6,578

11,989

2,986

20,997

14,717

-11,428

11,211

9,276

-6,676

Income taxes payable

10,056

-19,735

16,331

2,962

-6,271

8,634

-38,984

39,340

0

0

-

Deferred revenue

-5,414

-7,497

21,009

-1,315

-536

-1,203

-1,061

-1,205

-1,273

-2,540

-10,786

Contingent consideration

-

-

-

-

-

-14,900

0

0

-

-

-

Other non-current liabilities

3,561

14,537

18,934

23,199

26,562

17,724

14,820

2,351

-82

53

-

Operating lease liabilities, less current portion

-6,044

-

-

-

-

-

-

-

-

-

-

Liability under government settlement

-

-

-

-

-

-

-

-7,320

-3,786

-2,506

-1,984

Deferred rent

-

-

-

-

-

-

-

-

-

-

29

Net cash provided by operating activities

776,401

798,904

693,087

592,391

531,943

407,606

288,431

249,752

151,596

58,868

-15,878

Investing activities
Proceeds from maturity of investments

985,000

855,000

230,000

66,906

0

-

-

-

-

-

-

Purchases of property, plant and equipment

40,135

20,370

28,950

9,687

35,958

36,347

9,976

5,976

1,279

731

53

Acquired in-process research and development

61,700

0

85,000

23,750

0

202,626

4,988

0

-

-

-

Asset acquisition, net of cash acquired

55,074

0

0

1,502,443

0

828,676

0

542,531

0

0

-

Proceeds from sale of marketable securities

-

-

-

-

-

-

-

81,246

0

0

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

31,988

4,033

0

1,004

Acquisition of intangible assets

80,500

111,100

0

150,000

0

0

1,300

0

0

4,000

6,000

Acquisition of investments

917,100

1,165,915

385,000

132,181

0

0

-

-

-

-

-

Net proceeds from sale of assets

14,209

47,898

0

0

33,703

0

0

93,922

0

0

-

Purchases of marketable securities

-

-

-

-

-

-

-

37,443

79,886

0

-

Purchase of product rights

-

-

-

-

-

-

-

16,500

4,500

-

-

Decrease in restricted cash

-

-

-

-

-

-

-

-

-400

-2,588

1,075

Net cash (used in) provided by investing activities

-155,300

-394,487

-268,950

-1,751,155

-2,255

-1,067,649

-16,264

-395,294

-81,232

-2,143

-6,124

Financing activities
Proceeds from employee equity incentive and purchase plans

57,831

93,337

31,824

24,174

40,523

58,487

30,703

25,003

16,419

5,591

388

Payment of contingent consideration

-

-

-

-

-

35,100

0

0

-

-

-

Payment of employee withholding taxes related to share-based awards

16,739

17,925

18,589

21,234

26,102

18,030

5,590

25,299

0

0

-

Repayments of long-term debt

33,387

25,717

36,094

28,304

905,760

9,524

465,910

11,875

41,668

127,828

-

Share repurchases

301,450

523,672

98,799

278,296

61,553

42,215

136,484

0

0

-

-

Payment of debt modification costs

0

6,406

0

0

-

-

-

-

-

-

-

Repayments of Lines of Credit

0

0

850,000

150,000

160,000

300,000

0

0

-7,350

-2,049

5,524

Proceeds from tenant improvement allowance on build-to-suit lease

0

-1,253

-3,154

0

0

-

-

-

-

-

-

Net proceeds from issuance of debt

0

0

559,393

994,647

898,642

1,194,385

553,425

450,916

0

48,427

-

Excess tax benefit from share-based compensation

-

-

-

-

-

-

0

9,785

0

0

-

Acquisition of noncontrolling interests

-

-

-

-

73

136,969

0

0

-

-

-

Payments of debt extinguishment costs

-

-

-

-

-

-

-

-

483

8,484

-

Proceeds from offerings of common stock, net of issuance costs

-

-

-

-

-

-

-

-

-

56,817

6,782

Net cash used in financing activities

-293,745

-479,130

-409,111

540,987

-214,323

711,034

-23,856

448,530

-33,082

-27,526

12,694

Effect of exchange rates on cash and cash equivalents

366

-1,700

5,046

-5,045

-10,622

-3,453

997

2,132

0

0

-

Net increase in cash and cash equivalents

327,722

-76,413

20,072

-622,822

304,743

47,538

249,308

305,120

37,282

29,199

-9,308

Supplemental disclosure of cash flow information:
Cash paid for interest

43,002

42,706

44,609

39,898

40,099

31,978

18,278

14,192

1,621

10,234

24,488

Cash paid for income taxes

183,610

164,217

174,124

160,306

145,597

108,189

137,616

9,143

0

0

-

Non-cash investing activities:
Amounts capitalized in connection with facility lease obligations

0

27,747

40,970

23,799

4,351

0

0

-

-

-

-

Acquisition consideration for Azur Merger

-

-

-

-

-

-

-

576,464

0

-

-

Liability for purchase of product rights

-

-

-

-

-

-

-

-

-

-

5,000

Warrants to purchase common stock

-

-

-

-

-

-

-

-

-

-

2,700

Modification to warrants to purchase common stock issued in conjunction with long-term debt

-

-

-

-

-

-

-

-

-

-

1,254